Acasti Pharma Inc.

TSXV:ACST Voorraadrapport

Marktkapitalisatie: CA$19.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Acasti Pharma Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Jan D'Alvise

Algemeen directeur

US$1.8m

Totale compensatie

Percentage CEO-salaris25.1%
Dienstverband CEO6.8yrs
Eigendom CEO0.01%
Management gemiddelde ambtstermijn1.6yrs
Gemiddelde ambtstermijn bestuur1.4yrs

Recente managementupdates

Recent updates

Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Mar 01
Acasti Pharma (CVE:ACST) Is In A Good Position To Deliver On Growth Plans

Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Aug 17
Acasti Pharma (CVE:ACST) Is In A Strong Position To Grow Its Business

Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Jan 12
Is Acasti Pharma (CVE:ACST) In A Good Position To Invest In Growth?

Analyse CEO-vergoeding

Hoe is Jan D'Alvise's beloning veranderd ten opzichte van Acasti Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2022n/an/a

-US$17m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$11m

Mar 31 2022US$2mUS$445k

-US$10m

Dec 31 2021n/an/a

-US$12m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021US$582kUS$428k

-US$20m

Dec 31 2020n/an/a

US$3m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$21m

Mar 31 2020US$2mUS$411k

-US$26m

Dec 31 2019n/an/a

-US$56m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019US$926kUS$373k

-US$39m

Dec 31 2018n/an/a

-US$31m

Sep 30 2018n/an/a

-US$34m

Jun 30 2018n/an/a

-US$20m

Mar 31 2018US$891kUS$337k

-US$17m

Mar 31 2017US$631kUS$275k

-US$8m

Compensatie versus markt: Jan's total compensation ($USD1.77M) is above average for companies of similar size in the Canadian market ($USD172.33K).

Compensatie versus inkomsten: Jan's compensation has increased whilst the company is unprofitable.

CEO

Jan D'Alvise (67 yo)

6.8yrs

Tenure

US$1,773,841

Compensatie

Ms. Janelle D’Alvise, also known as Jan, has been an Independent Director of Spectral Medical Inc. since June 03, 2021. She is the Chairman of the board of The ObG Project. She has been the Chief Executive...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Janelle D'Alvise
President6.8yrsUS$1.77m0.015%
CA$ 2.8k
Pierre Lemieux
Co-Founder12.9yrsUS$905.45k0.0020%
CA$ 377.0
Brian Ford
Chief Financial Officer2.5yrsUS$847.55k0%
CA$ 0
George Kottayil
Chief Operating Officer of US1.6yrsUS$666.86k0%
CA$ 0
Prashant Kohli
Chief Commercial Officer1.2yrsUS$403.62k0.29%
CA$ 55.2k
Yves Lachance
Vice President of Quality & Compliance1.5yrsgeen gegevensgeen gegevens
Christine Pelletier
Senior Director of Human Resources1.2yrsgeen gegevensgeen gegevens

1.6yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: ACST's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Janelle D'Alvise
President6.7yrsUS$1.77m0.015%
CA$ 2.8k
Donald Olds
Independent Director4.9yrsUS$131.60k0.011%
CA$ 2.0k
Michael Derby
Independent Directorless than a yearUS$6.00kgeen gegevens
Jean-Marie Canan
Independent Director6.7yrsUS$134.10k0.028%
CA$ 5.4k
R. MacDonald
Member of Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Vimal Kavuru
Independent Director1.6yrsUS$96.60k0%
CA$ 0
Dariush Mozaffarian
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Andrew Ducruet
Member of Scientific Advisory Boardless than a yeargeen gegevensgeen gegevens
Alex Choi
Member of Scientific Advisory Board1.2yrsgeen gegevensgeen gegevens

1.4yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: ACST's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.